Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex

Cerebral Cortex

Volumn 18, Issue 6, 2008, Pages 1292-1301

  Rubino, T ^a   Realini, N ^a   Castiglioni, C ^a   Guidali, C ^a   Vigano D ^a   Marras, E ^a   Petrosino, S ^b   Perletti, G ^a   Maccarrone, M ^c,d   Di Marzo, V ^b   Parolaro, D ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF TERAMO   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Anandamide; Anxiety; CB1 receptors; FAAH; Prefrontal cortex; TRPV1 receptors

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; LENTIVIRUS VECTOR; METHANANDAMIDE; VANILLOID RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; EVOKED RESPONSE; GENE OVEREXPRESSION; MALE; MICROINJECTION; NEUROPHYSIOLOGY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; ARACHIDONIC ACIDS; BENZAMIDES; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; MALE; POLYUNSATURATED ALKAMIDES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1;

EID: 44449151954     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhm161     Document Type: Article

References (32)

1. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. 1997. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem. 272:3315-3323.
2. Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, Trezza V, La Rana G, Russo R, Calignano A, Gessa GL, et al. 2006. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology. 31:2652-2659.
3. Bremner JD, Vermetten E, Mazure CM. 2000. Development and preliminary psychometric properties of an instrument for the measurement of childhood trauma: the early trauma inventory. Depress Anxiety. 12:1-12.
4. Bystritsky A, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. 2001. Functional MRI changes during panic anticipation and imagery exposure. Neuroreport. 12:3953-3957.
5. De Lago E, Petrosino S, Valenti M, Morera E, Ortega-Gutierrez S, Fernandez-Ruiz J, Di Marzo V. 2005. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem Pharmacol. 70:446-452.
6. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1946-1949.
7. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. 2002. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids. 66:377-391.
8. Dilger S, Straube T, Mentzel HJ, Fitzek C, Reichenbach JR, Hecht H, Krieschel S, Gutberlet I, Miltner WH. 2003. Brain activation to phobia-related pictures in spider phobic humans: an event-related functional magnetic resonance imaging study. Neurosci Lett. 348:29-32.
9. Kasckow JW, Mulchahey JJ, Geracioti TD Jr. 2004. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry. 28:291-295.
10. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, et al. 2003. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 9:76-81.
11. Laviolette SR, Grace AA. 2006. Cannabinoids potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdala inputs. J Neurosci. 26:6458-6468.
12. Maccarrone M, Piccirilli S, Battista N, Del Duca C, Nappi G, Corasaniti MT, Finazzi-Agro A, Bagetta G. 2004. Enhanced anandamide degradation is associated with neuronal apoptosis induced by the HIV-1 coat glycoprotein gp120 in the rat neocortex. J Neurochem. 89:1293-1300.
13. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F, Di Marzo V. 2006. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther. 316:969-982.
14. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. 1998. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 55:715-720.
15. Marsch R, Foeller E, Rammes G, Bunck M, Kossl M, Holsboer F, Zieglgansberger W, Landgraf R, Lutz B, Wotjak CT. 2007. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci. 27:832-839.
16. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, et al. 2002. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 418:530-534.
17. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH. 2007. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology. 192:61-70.
18. Naldini L, Verma IM. 2000. Lentiviral vectors. Adv Virus Res. 55:599-609.
19. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, Eckelman W, Herscovitch P, Charney DS, Drevets WC. 2004. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci. 24:589-591.
20. Osti D, Marras E, Ceriani I, Grassini G, Rubino T, Vigano D, Parolaro D, Perletti G. 2006. Comparative analysis of molecular strategies attenuating positional effects in lentiviral vectors carrying multiple genes. J Virol Methods. 136:93-101.
21. Patel S, Hillard CJ. 2006. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther. 318:304-311.
22. Paxinos G, Watson C. 2005. The rat brain in stereotaxic coordinates. Burlington (MA): Elsevier Academic Press.
23. Ralevic V, Kendall DA, Randall MD, Zygmunt PM, Movahed P, Hogestatt ED. 2000. Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br J Pharmacol. 130:1483-1488.
24. Rodgers RJ, Evans PM, Murphy A. 2005. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol. 16:405-413.
25. Rodgers RJ, Haller J, Halasz J, Mikics E. 2003. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci. 17:1279-1286.
26. Ross RA. 2003. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol. 140:790-801.
27. Rubino T, Sala M, Vigano D, Braida D, Castiglioni C, Limonta V, Guidali C, Realini N, Parolaro D. 2007. Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology. 32:2036-2065.
28. Saghatelian A, McKinney MK, Bandell M, Patapoutian A, Cravatt BF. 2006. A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry. 45:9007-9015.
29. Shah AA, Treit D. 2003. Excitotoxic lesions of the medial prefrontal cortex attenuate fear responses in the elevated-plus maze, social interaction and shock probe burying tests. Brain Res. 969:183-194.
30. Shah AA, Treit D. 2004. Infusions of midazolam into the medial prefrontal cortex produce anxiolytic effects in the elevated plusmaze and shock-probe burying tests. Brain Res. 996:31-40.
31. Singewald N, Salchner P, Sharp T. 2003. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry. 53:275-283.
32. Sulcova E, Mechoulam R, Fride E. 1998. Biphasic effects of anandamide. Pharmacol Biochem Behav. 59:347-352.